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Abstract
Several chemotherapeutics exert immunomodulatory effects. One of these is the nucleoside analogue gemcitabine, which is
widely used in patients with lung cancer, ovarian cancer, breast cancer, mesothelioma and several other types of cancer, but
with limited efficacy. We hypothesized that the immunopotentiating effects of this drug are partly restrained by the
inhibitory T cell molecule CTLA-4 and thus could be augmented by combining it with a blocking antibody against CTLA-4,
which on its own has recently shown beneficial clinical effects in the treatment of patients with metastatic melanoma. Here
we show, using two non-immunogenic murine tumor models, that treatment with gemcitabine chemotherapy in
combination with CTLA-4 blockade results in the induction of a potent anti-tumor immune response. Depletion
experiments demonstrated that both CD4+ and CD8+ T cells are required for optimal therapeutic effect. Mice treated with
the combination exhibited tumor regression and long-term protective immunity. In addition, we show that the efficacy of
the combination is moderated by the timing of administration of the two agents. Our results show that immune checkpoint
blockade and cytotoxic chemotherapy can have a synergistic effect in the treatment of cancer. These results provide a basis
to pursue combination therapies with anti-CTLA-4 and immunopotentiating chemotherapy and have important
implications for future studies in cancer patients. Since both drugs are approved for use in patients our data can be
immediately translated into clinical trials.
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Introduction
Although in the past, orthodox clinical practice held that
chemotherapy and immunotherapy could not be combined
because of the myelosuppressive nature of most cytotoxic drugs,
this notion has been challenged in recent years by a large body of
experimental data (reviewed in [1,2]). For example, treatment with
anthracyclines and oxaliplatin results in immunogenic tumor cell
death and platinum-based chemotherapeutics downregulate the
inhibitory STAT6/PD-L2 pathway and sensitize tumor cells for T
cell-mediated cytotoxicity [3–5]. Our group has shown that the
nucleoside analog gemcitabine can enhance tumor antigen cross-
presentation by dendritic cells and others have shown that this
treatment leads to upregulation of tumor MHC class I expression
and depletion of both regulatory T cells and myeloid-derived
suppressor cells [6–10]. These data provide a strong rationale to
exploit the immunopotentiating effect of gemcitabine by combin-
ing it with other immunotherapeutic approaches.
Immunosuppressive networks play an important role in the
evasion of anti-tumor immunity, and as such could restrain the
immunopotentiating effect of chemotherapy. One of the poten-
tially relevant restraining pathways is mediated by the immune
inhibitory molecule Cytotoxic T-Lymphocyte Antigen 4 (CTLA-
4). The expression of CTLA-4 is upregulated following T-cell
activation and the pathway has been shown to play an important
immunomodulatory role in cancer. Therapeutic blockade of
CTLA-4 has been shown to be an effective treatment for
melanoma [11]. The anti-CTLA-4 monoclonal antibody ipilimu-
mab is now registered by the FDA as the first treatment that has
shown an overall survival benefit in a randomized phase III study
in metastatic melanoma in combination with dacarbazine
chemotherapy [12,13]. However, although some patients achieved
complete responses and others went on to long-term progression-
free survival, the majority of patients experienced disease pro-
gression.
We set out to determine if the CTLA-4 checkpoint limits the
potential therapeutic activity of gemcitabine by combining it with
a CTLA-4 blocking antibody. In this study we show for the first
time that CTLA-4 blockade and immunopotentiating chemother-
apy in a therapeutic dose have a synergistic effect, resulting in the
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induction of a potent anti-tumor immune response and long-term
protective immunity. In addition, we show that the overall efficacy
of the combination in mice is dependent upon the timing of
administration of the individual components.
Materials and Methods
Mice
BALB/C (H-2d) and C57BL/6 (H-2b) mice were obtained from
the Animal Resources Centre (Canning Vale, Australia) and were
maintained under standard conditions (M-Block Animal Facility,
Queen Elizabeth II Medical Centre, The University of Western
Australia). All mice used in these studies were between 8–12 weeks
of age.
Ethics Statement
All animal experiments were conducted according to The
University of Western Australia Animal Ethics Committee
approvals (protocol RA/3/100/1016) and the code of conduct
of the National Health and Medical Research Council of
Australia. The Western Australia Animal Ethics Committee
specifically approved this study.
Cell Lines
The MHC class I-positive, class II-negative, highly tumorigenic
and poorly immunogenic BALB/C-derived asbestos-induced
mouse mesothelioma cell line AB1, transfected with the influenza
HA gene (AB1-HA) has been described before [6,7]. For
rechallenge experiments non-HA-transfected AB1 cells were used.
The poorly immunogenic and highly tumorigenic Lewis Lung
Cancer (LLC) cell line was obtained from CellBank Australia
(Westmead NSW, Australia), where the identity of the cell line was
validated. Cell lines were maintained in RPMI 1640 (Invitrogen,
Mulgrave, Australia) supplemented with 20 mM HEPES,
0.05 mM 2-mercaptoethanol, 100 units/mL penicillin (CSL,
Melbourne, Australia), 50 mg/mL gentamicin (David Bull Labs,
Kewdale, Australia), and 10% FCS (Invitrogen). AB1-HA cells
were maintained in media containing the neomycin analogue
geneticin (Invitrogen) at a final concentration of 400 mg/mL. All
cell lines were regularly tested and remained negative for
Mycoplasma spp.
Tumor Challenge and Experimental Protocol
ABI-HA tumor cells (16106) or LLC (2.56105) in 100 ml PBS
were inoculated s.c. into the lower right flank of recipient mice.
Standard chemotherapy commenced 9 days later for AB1-HA and
6 days later for LLC when a palpable tumor of approximately 10
mm2 was evident. Mice were injected i.p. with gemcitabine
120 mg/g body weight every third day for five doses (q3dx5),
a regimen previously established as a maximal tolerated dose for
BALB/C mice (Figures S1, S2 and S3) [6,7]. Alternatively, mice
were treated with a single dose of cisplatin 6 mg/g on day 9 for
AB1-HA or day 6 for LLC, which we found to be the maximum
tolerated dose in this model based on titration experiments (data
not shown). Control mice received 100 ml PBS alone. Anti-CTLA-
4 was administered i.p. every third day for four doses (q3dx4).
Initially we used 100 mg per dose, but subsequent dose titration
studies showed that with 75 mg per dose equal results were
obtained and for that reason we took this dose for subsequent
experiments (Figure S4). In combination experiments using AB1-
HA with cisplatin, we used one single dose of 200 mg anti-CTLA-4
on day 9, based on a recent report demonstrating the feasibility
and potency of that schedule [14], and based on our own data
showing equivalency with the 75 mg q3dx4 schedule (data not
shown). Tumor size was measured using micro-calipers at least
three times weekly during the treatment and subsequently until
tumor size reached 100 mm2, at which point mice were
euthanized following regional animal ethics guidelines. During
treatment mice weights were monitored and culled if significant
weight loss (.15%) or toxicity was observed.
For some experiments mice that had shown complete regression
of tumors were rechallenged with non-HA transfected AB1
mesothelioma cells in the lower left flank (Figure S5). If at least
two months after rechallenge no tumors were palpable, the mice
were considered to be immune. Tumor-draining lymph nodes
were then collected and stained for memory T cell markers (see
below). Non-tumor-bearing naı¨ve mice were used as controls.
Antibodies and Chemotherapy
Gemcitabine (Gemzar, Eli Lilly) was supplied by the pharmacy
department of Sir Charles Gairdner Hospital. The anti-CTLA-4
(clone 9H10) monoclonal antibody was prepared and purified at
the Monoclonal Antibody Facility, WAIMR (Perth, Australia).
The CTLA-4 hybridoma was a kind gift from Prof. J.P. Allison
(Memorial Sloan Kettering Cancer Centre, New York, US).
For depletion experiments, the following antibodies were used:
anti-NK1.1 (clone PK136), anti-CD4 (clone GK1.5) and anti-CD8
(clone YTS169.4), all from the Monoclonal Antibody Facility,
WAIMR (Perth, Australia). Anti-CD4 and CD8 were adminis-
tered 150 mg i.v., one day before gemcitabine/anti-CTLA4,
followed by 100 mg i.p. every 3 days, last dose on day 27. Anti-
NK1.1 was administered 200 mg i.p on day 6, 9 and 12. Depletion
was confirmed by flow cytometry of peripheral blood from tail
bleeds (Figure S6).
The following antibodies were used for flow cytometry: CD3
FITC, CD4-PECy7, CD4 Pac Blue, CD8 PerCpCy5.5, CD3 PE
and ICOS APC, CD44-PE, CD49b FITC, CD62L-FITC, (all
Biolegend), Ki67 AF488, Ki 67 PE and CD4 APCH7 (all BD
Bioscience), CD3 PeCy7 FoxP3-PerCPCy5.5 and CD8 PECy7,
CD8 ef780 (eBioscience).
Cell Staining and Flow Cytometry Analysis
Peripheral blood sampling was performed via tail bleeds on day
29. A volume of ,100 ml of blood was collected in a heparin tube.
Antibody cocktails of surface stains (CD3, CD4, CD8 and ICOS)
were prepared and 20 ml added to 30 ml blood for 1 hour.
Samples were lysed (BD FACS lysing solution) and permeabilized
(eBioscience Fixation/Perm Buffer), the antibody for intracellular
staining (Ki-67) was prepared and 20 ml added for 45 mins.
Samples were resuspended in 200 ml stabilizing fixative (BD) and
50000 lymphocyte gated events were acquired on the FACS Canto
II flow cytometer (BD Biosciences) and data were analysed using
FlowJo software.
For some experiments, involving mice that had been cured with
treatment and subsequently resisted a rechallenge of tumor cells on
the contralateral flank, tumor-draining lymph nodes (TDLN) were
harvested (see above) for analysis of T memory cell subsets. Lymph
nodes from both flanks were harvested and pooled and stained for
CD4, CD8, CD44 and CD62L, according to the same protocol as
the flow cytometry analysis of peripheral blood (see above and
Figure S5).
For analysis of T cell responses in the tumor, TDLN (ipsilateral
axillary and inguinal nodes) and spleen, mice were culled on day
15 and the organs were harvested. Day 15 was chosen as time
point since from approximately day 12 the growth curves between
the groups started to divide, allowing adequate evaluation of T cell
responses. Spleens and LNs were mashed between glass slides,
resuspended in red blood cell lysis solution (eBioscience) and
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filtered through a 40 mm filter (BD) and stained with the relevant
antibodies. Tumors were minced finely and transferred to
digestion solution consisting of RPMI/2% FCS with 10 mg/ml
Collagenase and 1 mg/ml DNAse I (Sigma-Aldrich) and in-
cubated for 1 hour on a roller bank. During the last 10 minutes
EDTA was added to a final solution of 5 mM. Samples were
washed with RPMI/2%FCS and filtered through a 40 mm filter
and stained with the relevant antibodies.
Statistical Analyses
Data were analyzed using Prism 4.0 (GraphPad Software, Inc.).
Tumor growth data were analyzed using the PASW statistics
version 18 MIXED procedure (IBM SPSS, Chicago IL).
Comparisons between treatment groups at each time point were
adjusted for multiple comparisons by the Sidak method. Data for
tumor survival were analyzed according to the Kaplan Meier
method and survival proportions were compared between groups
using a Log Rank Test. Data from T cell subsets were compared
with the Student’s t test. Differences were considered significant
when the P value was ,0.05.
Results
Anti-CTLA-4 and Gemcitabine Combine in
a Therapeutically Synergistic Manner
Building on previous data demonstrating gemcitabine as an
immunogenic cytotoxic drug [7], we hypothesized that the
therapeutic efficacy of gemcitabine could be further enhanced
by combining it with a blocking antibody against CTLA-4. AB1-
HA-inoculated BALB/C mice were treated with anti-CTLA-4 in
combination with gemcitabine (Figure S1 and Figure 1). Treat-
ment with gemcitabine alone resulted in good control of tumor
outgrowth when the drug was administered, as previously
reported, however tumor progressed on cessation of treatment in
the majority of mice [15]. Treatment with anti-CTLA-4 alone
reduced the rate of tumor growth but was less effective than
gemcitabine as a monotherapy (Figure 1A). However, when anti-
CTLA-4 and gemcitabine were combined, a clear additive effect
of both treatments with a significant delay of tumor outgrowth was
observed. The number of animals that achieved complete
regression was superadditive (,60% in the combination group
versus ,13% for anti-CTLA-4 and ,8% for gemcitabine alone in
the AB1-HA model, Figs. 1A and B). We also found enhanced
tumor control in the LLC model, although the effect was less
pronounced (Figure S7). This accords with human studies using
immune checkpoint blocking antibodies, demonstrating major
differences in efficacy between different cancer types [16].
Interestingly, when we treated the mice with the non-immuno-
genic chemotherapeutic drug cisplatin [17], there was no clear
synergistic effect in either model (Figure 1C and D and Figure S7).
Previous studies in cancer patients and animals have suggested
that ICOS+ T cells play an important role in the action of anti-
CTLA-4, as well as having prognostic significance [18,19]. We
analyzed ICOS expression and proliferative status of circulating T
cells in the mice and found that mice that were treated with the
combination therapy showed a significant increase in CD4+ICOS+
T cells in peripheral blood, as well as a clear increase in CD4+
proliferative T cells as determined by Ki-67 staining (Figure 2A–
D, p,0.001).
To gain more insight into the composition of tumor-infiltrating
cells during treatment, we calculated the frequency of
Foxp3+CD4+ Tregs, CD49b+CD32 NK cells and ICOS+CD4+
activated Th cells and Ki-67+CD8+ proliferating CTLs in tumor,
tumor-draining lymph nodes (TDLN) and spleen on day 15
(Figure 2E–F, Figure S8). The percentage of CD8+ CTLs did not
differ between treatment groups (Figure S8), but their proliferative
capacity, as measured by Ki-67 did increase when mice were
treated with anti-CTLA4, both in tumor and TDLN. Interestingly,
the relative loss of proliferating tumor-infiltrating CD8+ T cells in
gemcitabine-treated mice was partly rescued by anti-CTLA-4
(Figure 2E). Tumor CD4+ T cell infiltration was not significantly
altered by either gemcitabine or anti-CTLA-4, although ICOS
expression as a marker of activation was decreased in all
gemcitabine-treated mice, either with or without anti-CTLA4
(Figure S8). The percentage of tumor-infiltrating Foxp3+CD4+ T
cells was significantly decreased in tumors treated with gemcita-
bine, anti-CTLA-4 or the combination treatment (Figure 2F),
a finding consistent with previously published data [10]. No clear
differences were observed in NK cell numbers between treatment
groups (Figure S8).
To investigate whether the enhanced response to the combina-
tion therapy involved mainly CD4+ or CD8+ T cells or NK cells
we performed depleting experiments using monoclonal antibodies
against CD4, CD8 (AB1-HA model) and NK1.1 (LLC model,
since BALB/C mice do not express NK1.1). We found that the
therapeutic effect of gemcitabine plus anti-CTLA4 was completely
abrogated when either CD4+ or CD8+ cells were depleted
(Figure 2G), whereas depletion of NK cells did not affect the
efficacy of the treatment (Figure S9). Taken together, these data
demonstrate that anti-CTLA-4 and chemotherapy synergize in the
induction of a potent anti-tumor immune response, with an
important role for both CD4+ and CD8+ T cells for optimal
therapeutic effect.
Anti-CTLA-4 and Gemcitabine Combination Therapy
Induces Long-lasting Protective Anti-tumor
Immunological Memory
One of the important theoretical advantages of immunotherapy
over chemotherapy is that the former has the potential to induce
immunological memory and therefore the potential to achieve
durable responses. We tested whether combination treatment with
anti-CTLA-4 and gemcitabine resulted in anti-tumor immuno-
logical memory. We reinoculated mice that had completely
rejected their tumors following combination treatment and found
that 93% (13 out 14 mice) of these mice were completely resistant
to tumor rechallenge (Figure 3A). Importantly, for rechallenge
experiments we used AB1 cells that were not transfected with HA,
indicating that the induced immunity was against shared tumor
antigens on the AB1 mesothelioma cells and not solely against the
transfected HA antigen. Flow cytometric analysis of T cell subsets
in the draining lymph nodes of these mice showed increased levels
of both central memory and effector memory CD4+ T cells, and to
a lesser extent CD8+ memory cells (Figure 3B–E, p,0.001).
Together, these data suggest that the combination treatment
results in an increase of memory T cells and the induction of
protective immunity.
Efficacy of Anti-CTLA-4/Gemcitabine Depends on Timing
In order to determine the optimal treatment schedule in terms
of timing of both anti-CTLA-4 and gemcitabine, we treated AB1-
HA tumor-bearing mice with three different regimes: gemcitabine
followed by anti-CTLA-4, concomitant combination therapy, and
anti-CTLA-4 followed by gemcitabine (Figure S3; Figure 4). One
animal in the anti-CTLA-4 followed by gemcitabine group was
culled because of weight loss greater than 15%, otherwise there
was no apparent toxicity. We observed marked differences in
tumor outgrowth between these groups (Figure 4). There was no
Anti-CTLA-4 and Cancer Chemotherapy
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significant additive value of the combination therapy over either
anti-CTLA-4 or gemcitabine alone when the chemotherapeutic
drug was administered separately from anti-CTLA-4. The
synergistic anti-tumor effect was only observed when the both
drugs were given concomitantly. Surprisingly, when only the first
dose of gemcitabine was omitted (as in the ‘anti-CTLA-4 first’ arm
versus the concomitant arm), the anti-tumor effect decreased
dramatically (Figure 4). These data show that appropriate
scheduling of the separate compounds is critical for optimal
efficacy.
Discussion
The combination of chemotherapy and immunotherapy in the
treatment of cancer holds unrealized promise [1]. The recently
FDA-approved anti-CTLA-4 antibody is a logical and easily
translatable immunotherapeutic approach to combine with
chemotherapy. We hypothesized that we would find a synergistic
interaction with a combination of anti-CTLA-4 blockade and an
immunopotentiating cytotoxic drug. We anticipated that the
chemotherapy would cause tumor shrinkage and immunogenic
antigen release while the anti-CTLA-4 would enhance T cell
activation and expansion. Prior data to support this hypothesis
were limited. A large phase III trial in metastatic melanoma
comparing anti-CTLA-4 plus DTIC versus DTIC alone found
a survival benefit for the combination therapy compared to DTIC
chemotherapy alone [13]. But because there was no comparison
with anti-CTLA-4 alone, the relative contribution of the
chemotherapy to the observed effect could not be accurately
assessed. Similarly, a phase II study in non-small cell lung cancer,
found improved progression-free survival for combination of
ipilimumab and chemotherapy versus chemotherapy alone; again
here ipilimumab alone was not a comparator [20]. In a phase II
study that did compare ipilimumab alone versus ipilimumab plus
DTIC, but using lower doses of study drug, there was a trend
towards better disease control rate for the combination arm, but
this did not reach significance [21]. Based on these published
human studies, no definitive conclusion can be drawn on a possible
synergistic effect of anti-CTLA-4 and chemotherapy. Although
a previous animal study did find enhanced anti-tumor efficacy
when anti-CTLA4 was added to melphalan chemotherapy, this
experiment used a subtherapeutic dose of melphalan, intended to
skew T cell responses towards a Th1 phenotype [22]. Recently,
Wu and colleagues found that anti-CTLA-4 treatment in
combination with cisplatin resulted in better disease control in
a murine mesothelioma model, when tumors were treated before
they were palpable, presumably due to inhibited cancer cell
repopulation [23]. We found no published animal data relevant to
our hypothesis, using therapeutic dosages of chemotherapy in
overt cancer.
Figure 1. Combination of CTLA-4 blockade and gemcitabine chemotherapy results in synergistic anti-tumor effect. (A) Tumor surface
in mm2 (mean 6 SD) of AB1-HA tumors that were injected on day 0, mice (n = 87) were treated on day 9/12/15/18 with 75 mg anti-CTLA-4 and with
120 mg/g gemcitabine on day 9/12/15/18/21, or with PBS (pooled data of 5 separate experiments are shown). (B) Kaplan-Meier survival plot of the
same experiment. (C) Tumor surface in mm2 (mean 6 SD) of AB1-HA tumors that were injected on day 0, mice (n = 65) were treated on day 9 with
200 mg anti-CTLA-4 and 6 mg/g cisplatin, or with PBS (pooled data from 3 separate experiments are shown). (D) Kaplan-Meier survival plot of the
same experiment.
doi:10.1371/journal.pone.0061895.g001
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As gemcitabine is widely used in the treatment of many cancer
types, including mesothelioma, we tested the combination in
a well–established non-immunogenic murine model of mesothe-
lioma. Treatment of AB1-HA with gemcitabine results in
moderate tumor reduction or delayed tumor outgrowth in this
model, thereby mimicking the clinical situation in the chemother-
apeutic treatment of most metastatic cancers.
We found here that combination therapy of gemcitabine and
anti-CTLA-4 exerted a far greater anti-tumor effect than either of
the agents alone, thus acting in a synergistic manner (Figure 1).
This correlated with a pronounced increase in CD4+ICOS+ T
cells in peripheral blood, as well as a clear increase in proliferating
CD4+ T cells as determined by Ki-67 staining, although we did
not detect this increase in the tumor as well (Figure 2). CD4+ T cell
infiltration in the tumor was enhanced by the combination
treatment, and a gemcitabine-associated decrease in proliferating
tumor-infiltrating CD8+ T cells was partly rescued by CTLA-4
blockade. Importantly, we did not find any reduction in tumor
growth when anti-CTLA-4 was combined with cisplatin. Cisplatin
has been shown to induce a non-immunogenic form of cell death
[17], and although it does downregulate the inhibitory molecule
PD-L2 [5], the tumor model we use expresses only very low levels
of PD-L2 (data not shown). Therefore, we consider cisplatin to be
a non-immunopotentiating form of chemotherapy in this model.
These results suggest that combination treatment with anti-CTLA-
4 will be most potent when combined with immunopotentiating
chemotherapy.
Since one of the theoretical advantages of combining chemo-
therapy with immunotherapy is the induction of a long-lasting
immunological memory, we investigated the memory T cell
response in mice with tumors that had regressed upon treatment
(Figure 3). We found that these mice had enhanced levels of both
CD4+ and CD8+ effector memory and central memory T cells in
the tumor-draining lymph nodes, correlating with protective
immunity to a rechallenge with tumor cells. These findings accord
with studies in a murine OVA-expressing Listeria monocytogenes
Figure 2. Combination of CTLA-4 blockade and gemcitabine chemotherapy results in enhanced T cell activation and proliferation
and is dependent on CD4+ and CD8+ T cells. A comparison is shown of peripheral blood T cell activation and proliferation markers on day 29
after inoculation for the different treatment groups (*p#0.05; **p,0.01***p,0.001). ICOS+/CD4+ Th cells (A); Ki-67+/CD4+ Th cells (B); CD8+/ICOS+
CTLs(C) and CD8+/Ki-67+ CTLs (D). (E and F) Flow cytometric analysis of proliferating CD8+ T cells and Treg in tumor, tumor-draining lymph node and
spleen on day 15. Depicted are the percentage of Ki-67+CD8+ of CD3+ cells and Foxp3+CD4+ of CD3+ cells (F). Six mice per group were tested for
control and anti-CTLA-4, 12 mice per group for gemcitabine-containing regimes pooled per 2 mice because of the small tumor size in these groups.
Means with SEMs are shown (n= 36). (G) Kaplan-Meier survival plot of AB1-HA tumors that were injected on day 0, mice (n = 57) were treated with
anti-CTLA-4 and/or gemcitabine, or with PBS in combination with depleting antibodies against CD4 or CD8 (pooled data of 2 separate experiments
are shown).
doi:10.1371/journal.pone.0061895.g002
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model, in which CD8+ T cell memory was enhanced by a single
dose of anti-CTLA-4 [14]. Importantly, in our model, neither the
formation of CD4+ nor CD8+ memory T cells was hampered by
gemcitabine.
Our third aim was to determine the optimal sequence of
chemotherapy and anti-CTLA-4 therapy. Since it is known from
several animal studies that timing is crucial in the use of anti-
CTLA-4 when combined with vaccination approaches [24,25], we
hypothesized that optimal timing/scheduling in combination with
chemotherapy would also be critical for anti-CTLA-4 efficacy. We
found that the efficacy of the combination indeed depended on
scheduling: if gemcitabine was administered before or after anti-
CTLA-4, there was no additive value above either therapy alone,
whereas concomitant treatment did result in disease control in the
majority of mice (Figure 4).
In conclusion, our results demonstrate that anti-CTLA-4
therapy and cytotoxic chemotherapy can have a clear synergistic
effect in the treatment of cancer. Our data provide a rationale to
further develop combinations of cytotoxic drugs and anti-CTLA-4
in the clinic. However, based on our data we suggest that for
Figure 3. Combination of CTLA-4 blockade and gemcitabine chemotherapy results in the induction of protective T cell memory. (A)
Kaplan-Meier survival plot of mice that had been cured by either anti-CTLA-4 alone or combination therapy and that were subsequently rechallenged
with AB1 mesothelioma cells, showing protective immunity in 80% and 92% respectively. T cell subset analysis in tumor-draining lymph nodes in
these mice (*p,0.05; **p,0.01***p,0.001): CD44+/CD62L+/CD4+ T central memory cells (B); CD44+/CD62L2/CD4+ T effector memory cells (C); CD44+/
CD62L+/CD8+ T central memory cells (D); CD44+/CD62L2/CD8+ T effector memory cells (E).
doi:10.1371/journal.pone.0061895.g003
Figure 4. The efficacy of combining CTLA-4 blockade with gemcitabine critically depends on timing. (A) Tumor area in mm2 (mean 6
SD) of AB1-HA tumors that were injected on day 0, mice (n = 86) were treated with different schedules of anti-CTLA4 and gemcitabine (see Figure S2),
or with PBS (pooled data of 3 separate experiments are shown). (B) Kaplan-Meier survival plot of the same experiment.
doi:10.1371/journal.pone.0061895.g004
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different groups of cytotoxic anti-cancer compounds, their optimal
schedule and immunogenicity should first be carefully determined
in pre-clinical models and small clinical studies.
Supporting Information
Figure S1 Treatment schedule of gemcitabine and anti-
CTLA-4 in the AB1-HA model. Balb/c mice were inoculated
with 16106 AB1-HA murine mesothelioma cells on day 0 and
subsequently injected i.p with PBS, 120 mg/g body weight
gemcitabine every third day for five doses (q3dx5) on days 9–
12–15–18–21 or 75 mg anti-CTLA-4 (q3dx4) on days 9–12–15–
18, either alone or in combination, as indicated.
(PDF)
Figure S2 Treatment schedule of gemcitabine and anti-
CTLA-4 in the LLC model. C57BL/6 mice were inoculated
with 2.56105 LLC murine lung cancer cells on day 0 and
subsequently injected i.p with PBS, 120 mg/g body weight
gemcitabine every third day for five doses (q3dx5) on days 6–9–
12–15–18 or 75 mg anti-CTLA-4 (q3dx4) on days 6–9–12–15,
either alone or in combination, as indicated.
(PDF)
Figure S3 Treatment schedule of combination therapy
of gemcitabine and anti-CTLA-4 in the AB1-HA model,
comparing different treatment schedules. Balb/c mice
were inoculated with 16106 AB1-HA murine mesothelioma cells
on day 0 and subsequently injected i.p with 120 mg/g body weight
gemcitabine (q3dx5) and 75 mg anti-CTLA-4 (q3dx4) divided over
three groups, ‘concurrent’ (anti-CTLA-4 on days 9–12–15–18;
gemcitabine on days 9–12–15–18–21), ‘anti-CTLA-4 first’ (anti-
CTLA-4 on days 9–12–15–18; gemcitabine on days 12–15–18–
21–24) and ‘gemcitabine first’ (gemcitabine on days 9–12–15–18–
21; anti-CTLA-4 on days 24–27–30–33).
(PDF)
Figure S4 Dose-optimisation study of anti-CTLA4 in the
AB1-HA model. Tumor surface in mm2 (mean 6 SD) of AB1-
HA tumors that were injected on day 0, mice (n = 40) were treated
with 75 mg anti-CTLA-4 i.p. on days 9–12–15–18 in the indicated
dosages and with gemcitabine 120 mg/g body weight on days 12–
15–18–21–24.
(PDF)
Figure S5 Gating strategy for determination of memory
T cell subsets in tumor-draining lymph nodes, using
flow cytometry. Tumor-draining lymph nodes were harvested
as described in the materials and methods section. Based on
forward and side scatter, populations enriched for lymphocytes
were gated, from which either CD4-PeCy7 positive or CD8-APC
positive cells were gated. Within these populations, the CD62L-
FITC and CD44-PE fluorescence signal were determined. Central
memory T cells were defined as CD44+/CD62Lhi, effector
memory T cells were defined as CD44+/CD62Llo.
(PDF)
Figure S6 Verification of depletion of CTL/Th/NK
cells. Mice were treated with aCD4/aCD8 (q3,dx7), starting
on day 8 with 150 mg i.v, followed by 100 mg i.p on days 11, 14,
17, 20, 23, 26. Representative peripheral tail bleeds on day 19 are
shown. Mice were treated with anti-NK1.1 (q3,dx3) starting on
day 6 with 150 mg i.v, followed by 200 mg i.p on days 9 and 12.
Representative peripheral tail bleeds on day 11 are shown.
(PDF)
Figure S7 Effect of combination treatment on tumor
outgrowth with chemotherapy and anti-CTLA-4 in the
LLC model. Tumor surface in mm2 (mean 6 SD) of LLC
tumors that were injected on day 0, mice (n = 57) were treated with
anti-CTLA-4 and/or gemcitabine or cisplatin. A representative of
3 separate experiments is shown (n = 30). The difference in tumor
outgrowth was significantly less for the combination treatment
from day 13 on when compared with anti-CTLA-4 alone and
from day 18 on when compared with gemcitabine alone (p,0.05).
(PDF)
Figure S8 Frequencies of CD4+ Th cells, CD8+ CTLs,
CD49b+CD3- NK cells and ICOS+CD4+ activated Th
cells in tumor, tumor-draining lymph nodes (TDLN) and
spleen. Populations were measured on day 15 (n = 36, 6 mice per
group for control and anti-CTLA-4, 12 mice per group for
gemcitabine-containing regimes pooled per 2 mice because of the
small tumor size in that groups), means with SEMs are shown
(*p,0.05).
(PDF)
Figure S9 The effect of NK-depletion on the efficacy of
gemcitabine and anti-CTLA-4 in the LLC model. Tumor
surface in mm2 (mean 6 SD) of LLC tumors that were injected on
day 0, mice (n = 57) were treated with anti-CTLA-4 and/or
gemcitabine in combination with an anti-NK1.1 depleting
antibody. A representative of 2 separate experiments is shown
(n = 20). Mice were treated with anti-NK1.1 (q3,dx3) starting on
day 6 with 150 mg i.v, followed by 200 mg i.p on days 9 and 12.
Anti-CTLA4 (q3,dx4) was administered 75 mg i.p on days 9, 12,
15, 18 and gemcitabine (q3,dx5) 120 mg/g i.p on days 9, 12, 15,
18, 21. NK depletion did not change the anti-tumor effect of
combination treatment with anti-CTLA-4 and gemcitabine.
(PDF)
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